Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality
worldwide. Effective prevention and management strategies are essential to reduce the …

Patients with cancer have elevated cardiovascular risks compared to those without cancer.
As cancer incidence increases and cancer-related mortality decreases, cardiovascular …

Background Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different
malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing …

Background This meta‐analysis aimed to determine the incidence and overall risk of major
adverse cardiovascular events (MACEs) related to immune checkpoint inhibitors (ICIs) …

Background: Routinely collected health data are increasingly used in clinical research. No
study has systematically reviewed the temporal trends in the number of publications and …

Introduction Previous studies on cardiovascular disease (CVD) death risk in cancer patients
mostly focused on overall cancer, age subgroups and single cancers. Objectives To assess …

Background Immune checkpoint inhibitors (ICI) are increasingly used in the first‐line
treatment of malignant tumors. There is increasing recognition of their cardiotoxicity and, in …

Since its designation as an emerging epidemic in 1997, heart failure (HF) has remained a
major public health problem (1). With an estimated 64.3 million people living with HF …

Background: Routinely collected health data are increasingly used for clinical or
epidemiological research. However, no study has systematically reviewed the temporal …